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Abstract
Background: Granulosa cell tumours (GCTs) are frequently seen in menopausal women and are
relatively indolent. Although the physiological properties of normal granulosa cells have been
studied extensively, little is known about the molecular mechanism of GCT progression. Here, we
characterise the unique behavioural properties of a granulosa tumour cell line, KGN cells, for the
molecular analysis of GCT progression.
Methods: Population doubling was carried out to examine the proliferation capacity of KGN cells.
Moreover, the invasive capacity of these cells was determined using the in vitro invasion assay. The
expression level of tumour markers in KGN cells at different passages was then determined by
Western blot analysis. Finally, the growth and metastasis of KGN cells injected subcutaneously (s.c.)
into nude mice was observed 3 months after injection.
Results: During in vitro culture, the advanced passage KGN cells grew 2-fold faster than the early
passage cells, as determined by the population doubling assay. Moreover, we found that the
advanced passage cells were 2-fold more invasive than the early passage cells. The expression
pattern of tumour markers, such as p53, osteopontin, BAX and BAG-1, supported the notion that
with passage, KGN cells became more aggressive. Strikingly, KGN cells at both early and advanced
passages metastasized to the bowel when injected s.c. into nude mice. In addition, more tumour
nodules were formed when the advanced passage cells were implanted.
Conclusion: KGN cells cultured in vitro acquire an aggressive phenotype, which was confirmed by
the analysis of cellular activities and the expression of biomarkers. Interestingly, KGN cells injected
s.c. are metastatic with nodule formation occurring mostly in the bowel. Thus, this cell line is a good
model for analysing GCT progression and the mechanism of metastasis in vivo.
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Background
GCTs are a relatively uncommon neoplasm; the incidence
of GCTs ranges from 1.6–3.0% in all cases of ovarian
tumour and comprises about 10% of all cases of ovarian
cancer [1]. They belong to the sex-cord stromal tumours
[2], and are classified as juvenile or adult, although the
majority of GCTs occur in menopausal women [3]. GCTs
are known to retain numerous characteristics of native
granulosa cells, such as the expression of active FSH recep-
tor, inhibin, and estrogen [4-6]. Although GCTs have a
malignant potential, they are often indolent and have a
propensity for late recurrence [7,8]. Up to 53% of all cases
lead to metastases within 5 years and studies encompass-
ing long-term follow-up have shown high mortality rates,
with about 50% of women dying from the disease within
20 years of diagnosis [9,10]. Although there have been
extensive studies on the biology of normal granulosa cells
[11,12], much knowledge of the molecular mechanism by
which transition from promotion to the progression stage
occurs in GCTs remains unknown.
To date, only seven human granulosa cell lines have been
established, [1,13-18] although several animal granulosa
cell-derived cell lines have been reported [14]. Of these,
KGN cells were generated from a GCT that recurred in the
pelvic region, and were shown to have detectable aro-
matase activity [1]. KGN cells have an abnormal karyo-
type (45, XX, 7q-, -22) which is probably related to the
tumourigenic character of this granulosa cell, as frequent
abnormalities in chromosome 7 have been reported in
ovarian tumours [19,20]. Interestingly, KGN cells
revealed a unique characteristic and grew progressively
faster during passages in our preliminary experiment.
Here, we investigated the specific characteristics of KGN
cells towards understanding the molecular pathogenesis
of GCTs. Because KGN cells grew much faster after pas-
sages in culture, we investigated their cellular characteris-
tics, such as proliferation capacity and invasiveness,
during passages in vitro. We then investigated the behav-
iour of these cells in vivo with the use of subcutaneous
xenografts at different passages.
Methods
Reagents
Hoechst 33342 and Mitomycin C from Streptomyces Caes-
pitosus, luteinizing hormone (LH) and follicle stimulating
hormone (FSH) were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Mouse monoclonal antibody
against p53 and osteopontin and rabbit polyclonal anti-
bodies against BAG-1 and BAX were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Goat
anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP were
purchased from Pierce Chemical Co. Ltd. (Woburn, MA,
USA) and Chemicon International Co. Ltd. (Temecula,
CA, USA), respectively.
Cell Culture
KGN cells were obtained from RIKEN Bioresource Center
(Tsukuba, Japan). Early (fewer than P10) and advanced
(more than P47) passage KGN cells were maintained as
described previously [21]. For detailed characterisation,
the cells were cultured in a medium supplemented with
10% charcoal/dextran-treated FBS (delipidated FBS,
Thermo Fishers Scientific Inc., South Logan, UT, USA), 0.1
IU/ml LH or 1IU/ml FSH. Cells were routinely passaged
after brief exposure to 0.25% trypsin with 0.02% EDTA in
PBS (-).
Evaluation of cellular morphology, proliferation and 
invasion
The morphology of KGN cells was observed under a
phase-contrast microscope (IX-71; Olympus, Tokyo,
Japan). The cellular proliferation was measured by popu-
lation doubling of KGN cells in a logarithmic growth
phase at a starting concentration of 2 × 105 cells/dish in 60
mm Petri dishes (Falcon, BD Japan, Tokyo, Japan). The
number of KGN cells was determined at 24 h interval for
4 days while changing the medium every other day. To
determine the proliferation rate of KGN cells at Day 4, a
colorimetric TetraColor ONE ELISA kit (SEIKAGAKU
CORPORATION, Tokyo, Japan) was utilised. Cells were
initially seeded at a density of 1 × 104 cells/well in 96-well
plates and the subsequent assay was carried out according
to the manufacturer's instructions. For invasion assay,
KGN cells (1 × 105 cells/well) suspended in serum-free
medium were seeded on the upper chamber coated with
Matrigel (200 μg/ml, Becton Dickinson, San Jose, CA,
USA). FBS (10%) was added to the medium in the lower
chamber and incubated for 12 h to allow cell invasion,
and then cells were fixed with 100% methanol. To exclude
the possibility that invasiveness was overestimated by dis-
tinct proliferation capacity of different passage cells, they
were treated with 10 μg/ml Mitomycin C for 2 h at 37°C
in a CO2 incubator and subjected to the invasion assay.
The cells retained in the upper chamber were scraped off
and stained with 10 μM Hoechst 33342 for 30 min at
room temperature. The number of cells that invaded
through the chamber was counted using an epi-fluores-
cence microscope. The experiments described above were
triplicated.
Chromosome analysis
The chromosomes were examined in exponentially grow-
ing early and advanced passage KGN cells (early: P6;
advanced: P53) in an in vitro culture. The karyotype of 10
KGN cells was analysed by standard trypsin G-banding, as
described previously [1].BMC Cancer 2008, 8:319 http://www.biomedcentral.com/1471-2407/8/319
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Western blot analysis
Cells were lysed in RIPA buffer containing protease inhib-
itor cocktails I and II (1:100 dilution, Sigma Chemical
Co) for 2 h at 4°C, and the insoluble materials were
removed by centrifugation (15,000 rpm, 15 min). The
protein concentration of samples was determined using a
micro BCA assay kit (Pierce Chemical Co. Ltd., Rockford,
IL, USA). Ten or fifty micrograms of samples per lane were
separated on a 12.5% reducing SDS polyacrylamide gel,
and transferred onto a PVDF membrane (Immobilon-P,
Millipore Japan, Tokyo, Japan). After blocking with 10%
goat serum plus 90% Blockace (SnowBrand, Tokyo,
Japan) at room temperature for 1 h, the membranes were
treated with the primary antibody and subsequently with
the secondary antibody. SuperSignal West Femto Maxi-
mum Sensitivity Substrate (Pierce, Rockford, IL, USA) was
used for visualisation, and the signal was developed on an
X-ray film (Amersham Bioscience, Piscataway, NJ). The
band intensity of each protein was measured using
ADOBE Photoshop Element 3.0 software and the back-
ground was subtracted. It was then divided by the band
intensity of β-actin for normalisation.
Tumour xenografts
The experiments were approved by the Animal Ethics
Committee at the National Center for Child Health and
Development, Japan. Six-week-old female BALB/c Foxn1/
Foxn1  mice (nude mice) were purchased from Sankyo
Labo Service Co. Ltd. (Tokyo, Japan). The early or
advanced passage KGN cells (5 × 106 cells) were harvested,
resuspended in 200 μl of PBS, and injected s.c. into both
flanks of each mouse (early; n = 9, advanced; n = 9). Mice
were euthanized and examined for tumour generation
after 3 months, and the number of nodules formed in the
bowel was counted. The experiments were quadrupli-
cated.
Histological evaluation
For light microscopic analysis, the metastases formed in
the bowel were fixed with 4% formaldehyde, paraffin-
embedded, sectioned at 4 μm intervals and stained with
hematoxylin-eosin.
Semi-quantitative RT-PCR analysis
The small intestine with or without metastases was
obtained from four mice in each group (control, the
'early', and the 'advanced' groups) and total RNA was iso-
lated with the use of ISOGEN RNA isolation reagent (Nip-
pon Gene Co. Ltd., Tokyo, Japan). Reverse transcription
was conducted, as described previously [21]. The expres-
sion of p53 was monitored by PCR amplification. The
specific primers for human p53 and GAPDH and cycles
used for each gene were as follows; p53 forward primer:
CAGCCAAGTCTGTGACTTGCACGTAC, p53 reverse
primer: CTATGTCGAAAAGTGTTTCTGTCATC, 35 cycles;
GAPDH forward primer: ACCACAGTCCATGCCATCAC,
GAPDH reserve primer: TCCACCACCCTGTTGCTGTA, 28
cycles. The conditions for PCR amplification were: initial
denaturation at 94°C for 5 min, followed by the indicated
cycles of denaturation at 94°C for 45 s, annealing at 57°C
for 45 s, and elongation at 72°C for 1 min, with a final
extension of 72°C for 15 min. The image analysis of the
PCR product was performed as described previously [21].
Statistical analysis
The average data on population doubling, proliferation,
invasion and metastasis were presented as means with
SEM from three independent experiments. Statistical anal-
yses were conducted by Student's or modified t-test using
Microsoft Excel software. Differences were considered sta-
tistically significant when P < 0.05.
Results
Characterisation of KGN cells in vitro
KGN cells appeared to grow faster during passages in our
preliminary experiments. For detailed characterisation of
KGN cells, early and advanced passage cells were cultured,
and the proliferation capacity was monitored. Growth of
the advanced passage cells turned out to be significantly
faster than that of the early passage cells, determined by
population doubling evaluation (Fig 1A and 1B, about 2-
fold increase at Days 3 and 4, P < 0.05, P < 0.01). The
behavioural changes of KGN cells at different passages
occurred without any morphological changes at Days 1
and 4 (Fig 1A).
Next, we conducted an in vitro invasion assay to assess the
characteristic features of the tumours. Along with
increased proliferative activity, the advanced passage cells
were 2-fold more invasive than the early passage cells (Fig
1C, P < 0.01). Since the advanced passage cells were more
proliferative than the early passage cells, KGN cells were
treated with Mitomycin C to prevent proliferation during
the invasion assay. Loss of proliferative capacity of the
advanced passage cells was confirmed by the TetraColor
ONE proliferation assay (OD450; untreated early passage
cells: 0.10; untreated advanced: 0.18; treated early: 0.09;
treated advanced 0.10). Under the conditions of the assay,
the advanced passage cells remained more invasive than
the early passage cells (Fig 1D, P < 0.01), suggesting that
the increased invasiveness was not related to proliferation.
Because serum factors and hormones may be involved in
GCT progression, KGN cells were cultured in a medium
containing delipidated FBS, LH or FSH, and subjected to
the proliferation assay. As shown in Fig 2, none of these
treatments affected the characteristics of the early and
advanced passage cells.BMC Cancer 2008, 8:319 http://www.biomedcentral.com/1471-2407/8/319
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Karyotype analysis
G-banded karyotype analyses of 10 early and advanced
KGN cells revealed that all the cells exhibited 45 chromo-
somes (data not shown), as described previously [1].
Expression of various tumour markers in KGN cells at 
different passages
Subsequently, we examined the expression level of malig-
nant tumour markers in the early and advanced passage
cells (Fig 3A, B). Initially, we determined the expression
level of p53, which has been reported to be a prognostic
marker of metastasis in granulosa cell tumours [9,22]. As
expected, the expression level of p53 was up-regulated in
Characterization of KGN cells at different passages Figure 1
Characterization of KGN cells at different passages. (A) Morphology of KGN cells at Days 1 and 4 (P9 vs. P58). (B) 
Population doubling measured for 4 days using the early and advanced passage KGN cells seeded at 2 × 105 cells/dish (P9 vs. 
P58). (C, D) Invasiveness of different passage KGN cells (P6 vs. P53). Cells in serum-free medium at a concentration of 1 × 105 
cells/well were subjected to an invasion assay using transwell chambers coated with Matrigel for 12 h (C; normal cells, D; Mito-
mycin C-treated cells). The proliferation of Mitomycin C-treated cells was blocked, as determined by the TetraColor One pro-
liferation assay. All experiments were triplicated and the data are shown as the mean number with SEM. Statistical difference 
was analysed by Student's t-test (*P < 0.05).
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the advanced passage cells. Next, we performed immuno-
blots for osteopontin, which is a biomarker of tumour
progression [23], and found that it markedly increased in
the advanced passage cells. Furthermore, we examined the
expression of BAX and BAG-1, which are known biomar-
kers of apoptosis [24]. As expected, BAX was up-regulated,
whereas BAG-1 was down-regulated in the advanced pas-
sage cells, suggesting that the advanced passage cells
might be resistant to apoptosis. These results strongly
indicate that KGN cells became aggressive during passages
in vitro.
Tumour growth in vivo
Further characterisation of KGN cells was performed using
an in vivo tumour growth assay in nude mice. As shown in
Fig 4A, the xenograft of the advance passage cells devel-
oped faster than that of the early passage cells at the region
where KGN cells were injected, and larger clumps under
the skin were observed (in the small windows of Fig 4A).
More interestingly, KGN cells at both the early and
advanced passages metastasized from the subcutaneous
transplanted region to the bowel, especially in the submu-
cosa of the small intestine, but not to the other tissues
(metastases in the bowel were seen in 7 out of 9 mice
transplanted) (Fig 4B). Although an increased number of
nodules were formed in the bowel by transplantation of
the advanced passage cells (Fig 4C, P < 0.05), the size of
nodules obtained using both passage cells was similar (3
mm × 3 mm).
To confirm the origin of nodules, the expression of a GCT-
specific marker in the nodules was examined by RT-PCR
using human-specific primers. As shown in Fig 4D,
human p53 mRNA was found to be expressed in the nod-
ules, suggesting that the nodules originated from KGN
cells. Moreover, histological analysis revealed that the
cells at both passages exhibited a coffee bean-like nuclear
appearance, which is typically observed in specimens of
granulosa cell origin (Fig 5). These results demonstrated
that KGN cells metastasized from the subcutaneous
region to the bowel.
Proliferation of KGN cells at different passages Figure 2
Proliferation of KGN cells at different passages. The early (P6) and advanced (P58) passage KGN cells were cultured in 
10% delipidated FBS, 0.1 IU/ml LH, or 1 IU/ml FSH, seeded at 1 × 104 cells/well in 96-well plates and subjected to the prolifer-
ation assay. The experiments were triplicated and the data are shown as the mean absorbance with SEM (at OD 450 nm). Sta-
tistical analysis was conducted using Student's t-test.
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Expression of tumour markers in KGN at different passages Figure 3
Expression of tumour markers in KGN at different passages. Western blot analysis of KGN cells at P7 and P51 was 
conducted to examine the expression level of p53, osteopontin, BAX and BAG-1. Ten μg (for BAX and BAG-1) or 50 μg (for 
p53 and osteopontin) of whole cell extract were separated on a 12.5% reducing gel. The lower panel represents the mean 
intensity of each band normalised by dividing with the intensity of β-actin.
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Figure 4 (see legend on next page)
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Discussion
In the previous study, KGN cells were shown to retain
properties of normal granulosa cells, such as aromatase
activity and progesterone synthesis [1]. Despite the fact
that KGN cells can be maintained in more than 100 pas-
sages, their native properties are unchanged during pas-
sages. Moreover, we confirmed progesterone synthesis in
the advanced passage cells in response to cAMP, and that
chromosomal instability did not occur during passages
determined by G-band analysis (data not shown). There-
fore, the transformation of KGN cells during passages
occurs without loss of their native characteristics.
The mechanism responsible for the phenotypic transfor-
mation of the cells during passages remains uncertain.
One possibility is that a minor population of aggressive
GCTs included in the early passage cells prevailed during
passages, resulting in an overall aggressive character.
Although cloning of the early passage cells (7 clones
examined) did not show any changes in phenotype
among the clones (data not shown), this possibility could
not be ruled out. The second possibility is that oxidative
stress gained during in vitro culture may have prompted
the transformation. Although administration of hydrogen
peroxide to the culture of KGN cells did not affect their
behaviour in our study (data not shown), it is likely that
oxidative stress during in vitro culture may induce genome
instability and mutation in these cells. The third possibil-
ity is that hormones, such as estrogen and progesterone,
secreted from KGN cells influence the transformation.
Although high expression level of estrogen receptor β
(ERβ), a potent suppressor of proliferation, has been
reported in GCTs [25], direct interaction between ERβ and
NF-κB might be required for GCTs survival [26]. However,
exogenous administration of hormones, such as estrogen,
LH and FSH, to the culture did not enhance the transfor-
mation. Another possibility might be that cytokines and
other growth factors present in FBS may influence the cel-
lular phenotype, although we determined that at least
EGF did not influence on the proliferation of KGN cells
(data not shown). Therefore, further analysis is required
to elucidate the exact mechanism involved in the transfor-
mation of KGN cells in vitro.
Spontaneous changes in cellular characteristics during in
vitro culture are, more or less, common among different
cell types. In fact, several cell lines have been reported to
undergo in vitro transformation into a malignant pheno-
type [27-29]. Conversely, human tumours implanted s.c.
in nude mice are known to have little metastatic capability
[30]. However, KGN cells were found to be metastatic
with nodule formation occurring mostly in the bowel.
Because the nodules were formed in the submucosa of the
small intestine, they must have not metastasized perito-
neally. However, the route of KGN cells to the bowel
remains uncertain. Although it seems that the metastases
develop slowly since the tumour nodules of KGN cells
remained small in size after 3 months of transplantation
and histological evaluation (3 mm × 3 mm), this cell line
may be useful for research on metastasis.
Conclusion
We characterised KGN cells as a malignant tumour model
of GCTs. Continuously cultivated KGN cells acquire an
aggressive phenotype, confirmed by the analysis of cellu-
lar activities and the expression of biomarkers. More strik-
ingly, KGN cells injected under the skin were metastatic
with nodule formation occurring mostly in the bowel.
Thus, this cell line is a good model for analysing GCT pro-
gression and the mechanisms of metastasis.
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Growth and metastases of KGN cells in nude mice Figure 4 (see previous page)
Growth and metastases of KGN cells in nude mice. KGN cells at the early (P7) and advanced (P58) passages were transplanted 
in the flanks of nude mice at a concentration of 5 × 106 cells. After 3 months, the growth of KGN cells at the injected region 
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Histology of metastases in nude mice Figure 5
Histology of metastases in nude mice. The bowel containing the tumour nodules was paraffin-embedded, sectioned at 4 
μm intervals and stained with hematoxylin-eosin. The left panels represent the lower magnification of the bowel with or with-
out tumour nodules (×40, P7 vs. P59). The squared regions in the left panels are enlarged in the right panels (×400).BMC Cancer 2008, 8:319 http://www.biomedcentral.com/1471-2407/8/319
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